CORRESP Filing
aTYR PHARMA INC
Date: Aug. 13, 2025 · CIK: 0001339970 · Accession: 0001339970-25-000018
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289360
Letter
Re: aTyr Pharma, Inc.
aTyr Pharma, Inc . 10240 Sorrento Valley Road, Suite 300 San Diego, California 92121 August 14, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Tyler Howes
Registration Statement on Form S-3
Filed: August 7, 2025
File No. 333-289360
Ladies and Gentlemen: aTyr Pharma, Inc. (the “ Registrant ”) hereby requests that the U.S. Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on August 18, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Charles Bair and Nicholaus Johnson of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Charles Bair of Cooley LLP at (858) 550-6142 or, in his absence, Nicholaus Johnson of Cooley LLP at (858) 550-6198. [ Signature Page Follows ]
Very truly yours, ATYR PHARMA, INC.
By:
/s/ Jill M. Broadfoot
Show Raw Text
CORRESP 1 filename1.htm CORRESP aTyr Pharma, Inc . 10240 Sorrento Valley Road, Suite 300 San Diego, California 92121 August 14, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Tyler Howes Re: aTyr Pharma, Inc. Registration Statement on Form S-3 Filed: August 7, 2025 File No. 333-289360 Ladies and Gentlemen: aTyr Pharma, Inc. (the “ Registrant ”) hereby requests that the U.S. Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on August 18, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Charles Bair and Nicholaus Johnson of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Charles Bair of Cooley LLP at (858) 550-6142 or, in his absence, Nicholaus Johnson of Cooley LLP at (858) 550-6198. [ Signature Page Follows ] Very truly yours, ATYR PHARMA, INC. By: /s/ Jill M. Broadfoot Name: Jill Broadfoot Title: Chief Financial Officer cc: Charles Bair, Cooley LLP Nicholaus Johnson, Cooley LLP Nancy Denyes, aTyr Pharma, Inc. [ Company Signature Page to Acceleration Request ]